Alport Syndrome
30
9
11
13
Key Insights
Highlights
Success Rate
81% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
10.0%
3 terminated out of 30 trials
81.3%
-5.3% vs benchmark
10%
3 trials in Phase 3/4
46%
6 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 13 completed trials
Clinical Trials (30)
A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome
Periodontal Disease in Rare Renal Disorders (PERIO-RA-RE)
Albuminuria Lowering Effect of Dapagliflozin, Spironolactone and Their Combination in Adult Patients With Alport Syndrome (COMBINE-ALPORT)
NEPTUNE Match Study
Atrasentan in Patients With Proteinuric Glomerular Diseases
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
ASF Alport Patient Registry
A Study to Evaluate Setanaxib in Patients With Alport Syndrome
A Study of ELX-02 in Patients With Alport Syndrome
Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1)
Alport Syndrome Treatments and Outcomes Registry
Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis
Eurbio-Alport (RaDiCo Cohort) (RaDiCo Eurbio-Alport)
Study of Lademirsen (SAR339375) in Patients With Alport Syndrome
Baby Detect : Genomic Newborn Screening
A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL
An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome
Human Umbilical Cord Mesenchymal Stem Cells for Alport Syndrome
Effects of Dapagliflozin on Progression of Alport Syndrome